Research programme: CXCR4 inhibitors - Kureha

Drug Profile

Research programme: CXCR4 inhibitors - Kureha

Alternative Names: CS-3955; KRH-3955

Latest Information Update: 13 Sep 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kureha Corporation
  • Class
  • Mechanism of Action CXCR4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical HIV infections

Most Recent Events

  • 07 May 2009 Preclinical trials in HIV infections in Japan (PO)
  • 12 May 2008 No development reported - Preclinical for HIV infections in Japan (PO)
  • 28 Feb 2007 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top